Crossmark

Insights on postneoadjuvant treatment among patients with triple-negative breast cancer and residual disease after neoadjuvant therapy: can expert consensus help to interpret the current evidence?

Crossref DOI link: https://doi.org/10.1038/s41416-026-03452-8

Published Online: 2026-04-29

Published Print: 2026-08-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Valachis, Antonis https://orcid.org/0000-0001-6059-0194
Geisler, Jürgen https://orcid.org/0000-0001-6239-3856
Karihtala, Peeter https://orcid.org/0000-0003-3490-3702
Tuxen, Malgorzata K.
License Information

Text and Data Mining valid from 2026-04-29

Version of Record valid from 2026-04-29
More Information

Article History

Received: 2 November 2025

Revised: 12 March 2026

Accepted: 9 April 2026

First Online: 29 April 2026

Ethics

Competing interests: AV: unrestricted institutional grant from Roche and MSD. JG: No conflict of interests to declare. PK: member of the advisory board, speaker, or expert testimony for Amgen, Astellas, AstraZeneca, Daichii Sankyo, Gilead, Lilly, Menarini Stemline, MSD, Novartis, Pfizer, Roche and Sandoz. MKT: member of the advisory board or consultant for AstraZeneca, Daichii Sankyo, Lilly, Gilead, MSD, Novartis, Pfizer.

Document is current

Any future updates will be listed below